Indian Journal of Paediatric Dermatology

ORIGINAL ARTICLE
Year
: 2022  |  Volume : 23  |  Issue : 1  |  Page : 28--32

Should all infantile hemangiomas be treated? − Time to learn, unlearn, and relearn


Sanober Burzin Daruwalla1, Niti Khunger2, Akshay Kumar3, Rachita S Dhurat1 
1 Department of Dermatology, LTMMC and LTMGH, Mumbai, Maharashtra, India
2 Department of Dermatology, VM Medical College and Safdarjung Hospital, New Delhi, India
3 Department of Dermatology, Government Medical College, Kota, Rajasthan, India

Correspondence Address:
Sanober Burzin Daruwalla
Department of Dermatology, LTMMC and LTMGH, Sion West, Mumbai - 400 022, Maharashtra
India

Introduction: The quality of life of both the child and their caretakers has been noted to be adversely affected by visible birthmarks and resultant scarring, particularly in areas that cannot be easily covered. With the current knowledge about the uncertain trend in the progression of infantile hemangiomas (IH), the risks associated with it, and the availability of safe and effective treatment options available, a question arises, that should all hemangiomas be treated? A national survey was conducted to determine dermatologists' opinions throughout the country followed by the analysis and literature review. Methodology: An anonymous questionnaire of 10 questions was shared among dermatologists of the country using a link distributed through the electronic media. The data submitted anonymously by the responders were analyzed after due permission for its use for research and publication was received. Results: A total of 91 clinicians completed the questionnaires. 54.95% of the respondents answered that they would wait and watch in the majority of the cases presenting to them. 83.52% of the responders chose topical timolol as the most common medical treatment modality. 33.71% of the responders reported the resolution of IH in more than 75% of their patients and fibrofatty residue was the most common sequelae reported post the involuntary stage. 65.56% of the responders answered no to the question − “Should all hemangiomas be treated?” Conclusion: Clinical experience backed with research has proved the efficacy of beta-blockers in the resolution of IH beyond doubt. The need to identify, evaluate, and initiate timely treatment is required to avoid missing the window of opportunity to optimize the outcomes.


How to cite this article:
Daruwalla SB, Khunger N, Kumar A, Dhurat RS. Should all infantile hemangiomas be treated? − Time to learn, unlearn, and relearn.Indian J Paediatr Dermatol 2022;23:28-32


How to cite this URL:
Daruwalla SB, Khunger N, Kumar A, Dhurat RS. Should all infantile hemangiomas be treated? − Time to learn, unlearn, and relearn. Indian J Paediatr Dermatol [serial online] 2022 [cited 2022 Jan 28 ];23:28-32
Available from: https://www.ijpd.in/article.asp?issn=2319-7250;year=2022;volume=23;issue=1;spage=28;epage=32;aulast=Daruwalla;type=0